Core 1: Biospecimens Core
Core 1: Biospecimens Core
批准号:
10729278
负责人:
Jann N. Sarkaria
金额:
$34.82万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-15 至 2028-08-31
关键词:
Animal ExperimentsAnimal ModelAnimalsArchivesBiologicalBiological ModelsBrainBrain NeoplasmsCategoriesCellsClinicClinical TrialsCollaborationsCollectionComplexCoupledEnsureFutureGenetically Engineered MouseGlioblastomaGoalsHumanImmunologicsIntracranial NeoplasmsLaboratoriesModelingNeuronsNeurosurgeonOrganoidsPatientsPilot ProjectsResearch Project GrantsResearch SupportResourcesRetrievalSamplingScientistSignal TransductionSliceSpecimenSystemSystems AnalysisSystems BiologyTissuesTranslationsWorkWritingbench to bedsidebiobankbiological specimen archivesclinically relevantdesignexperienceexperimental studyimage registrationin vivoneoplastic cellneuro-oncologypatient derived xenograft modelpharmacologicpre-clinicalpreclinical studyprospectivequality assurancetumortumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT – BIOSPECIMENS CORE
The Biospecimens Core will serve as a central resource to coordinate provision of highly translationally
relevant animal and human analytical specimens for use in both main research projects and likely several of
the anticipated pilot projects. To maximize the translation relevance of the analyses performed on animal
specimens, patient-derived xenografts (PDXs) and genetically engineered mouse models (GEMMs) of
glioblastoma (GBM) will be used for our pre-clinical studies. We have extensive experience using these models
for evaluating the systems biology of intracranial tumors and how pharmacologic manipulations dysregulate
critical signaling nodes within these systems. Coupled with these preclinical studies, analysis of operative
specimens from GBM patients provides a ‘ground-truth’ for the biological modeling performed. In this context,
the Biospecimens Core will capitalize on established collaborations with neurosurgeons at both DFCI and
Mayo Clinic and the extensive Neuro-Oncology Biobank available at Mayo Clinic for provision of both archived
tumor samples and prospective analysis of image-registered, fresh operative specimens. Derivative cell,
organoid, and tissue-slice cultures from both animal and human biospecimens also will be used to enable
reverse translation of key findings and to further refine or validate our systems analyses. To capitalize on
opportunities for coordinated analyses of the same biological samples across both Projects, a Scientific
Manager will coordinate biospecimen collection, quality assurance review, shipment and analyses across
laboratories and projects. The Core also will ensure appropriate regulatory review and approvals are in place
to support both the animal and human biospecimen collections and analyses. The overall efforts of the Core
can be divided into two Aims to support animal and human GBM studies.
Specific Aim 1: Develop, manage, and execute in vivo studies in tumor-bearing animals
Specific Aim 2: Coordinate the collection and distribution of human biospecimens
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of the brain penetrant ATM inhibitor WSD0628 in combination with radiation for recurrent high grade glioma
-
批准号:10730230
-
项目类别:
-
资助金额:$64.93万
-
财政年份:2023
-
负责人:Jann N. Sarkaria
-
依托单位:
Administrative Core
-
批准号:10305362
-
项目类别:
-
资助金额:$12.11万
-
财政年份:2021
-
负责人:Jann N. Sarkaria
-
依托单位:
Therapy Evaluation Core
-
批准号:10704626
-
项目类别:
-
资助金额:$33.92万
-
财政年份:2021
-
负责人:Jann N. Sarkaria
-
依托单位:
MDM2 inhibitor therapy for TP53 wild-type GBM
-
批准号:10305366
-
项目类别:
-
资助金额:$17.28万
-
财政年份:2021
-
负责人:Jann N. Sarkaria
-
依托单位:
Therapy Evaluation Core
-
批准号:10305363
-
项目类别:
-
资助金额:$17.53万
-
财政年份:2021
-
负责人:Jann N. Sarkaria
-
依托单位:
Therapy Evaluation Core
-
批准号:10492768
-
项目类别:
-
资助金额:$15.51万
-
财政年份:2021
-
负责人:Jann N. Sarkaria
-
依托单位:
Administrative Core
-
批准号:10704625
-
项目类别:
-
资助金额:$22.89万
-
财政年份:2021
-
负责人:Jann N. Sarkaria
-
依托单位:
MDM2 inhibitor therapy for TP53 wild-type GBM
-
批准号:10704631
-
项目类别:
-
资助金额:$24.6万
-
财政年份:2021
-
负责人:Jann N. Sarkaria
-
依托单位:
MDM2 inhibitor therapy for TP53 wild-type GBM
-
批准号:10492775
-
项目类别:
-
资助金额:$15.52万
-
财政年份:2021
-
负责人:Jann N. Sarkaria
-
依托单位:
Administrative Core
-
批准号:10492764
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2021
-
负责人:Jann N. Sarkaria
-
依托单位:
Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain Tumors
-
批准号:10405050
-
项目类别:
-
资助金额:$55.23万
-
财政年份:2018
-
负责人:Jann N. Sarkaria
-
依托单位:
The Mayo GBM Xenograft National Resource
-
批准号:9356585
-
项目类别:
-
资助金额:$25.88万
-
财政年份:2016
-
负责人:Jann N. Sarkaria
-
依托单位:
Admin-Core-001
-
批准号:10025666
-
项目类别:
-
资助金额:$10.24万
-
财政年份:2016
-
负责人:Jann N. Sarkaria
-
依托单位:
Admin-Core-001
-
批准号:10025667
-
项目类别:
-
资助金额:$10.24万
-
财政年份:2016
-
负责人:Jann N. Sarkaria
-
依托单位:
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
-
批准号:9902827
-
项目类别:
-
资助金额:$10.24万
-
财政年份:2016
-
负责人:Jann N. Sarkaria
-
依托单位:
MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors
-
批准号:9187647
-
项目类别:
-
资助金额:$215.22万
-
财政年份:2016
-
负责人:Jann N. Sarkaria
-
依托单位:
Influence of DNA repair on PARP Inhibitor efficacy In GBM
-
批准号:8729252
-
项目类别:
-
资助金额:$27.68万
-
财政年份:2014
-
负责人:Jann N. Sarkaria
-
依托单位:
(PQD3) Mechanisms of prolonged initial disease-free survival in glioblastoma
-
批准号:9262163
-
项目类别:
-
资助金额:$73.83万
-
财政年份:2014
-
负责人:Jann N. Sarkaria
-
依托单位:
(PQD3) Mechanisms of prolonged initial disease-free survival in glioblastoma
-
批准号:9050645
-
项目类别:
-
资助金额:$73.83万
-
财政年份:2014
-
负责人:Jann N. Sarkaria
-
依托单位:
(PQD3) Mechanisms of prolonged initial disease-free survival in glioblastoma
-
批准号:8680866
-
项目类别:
-
资助金额:$66.91万
-
财政年份:2014
-
负责人:Jann N. Sarkaria
-
依托单位:
海外基金